Patents by Inventor Kazuhiro Uemoto
Kazuhiro Uemoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9714213Abstract: A compound represented by general formula (1) a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C1-C6 alkyl group; A represents a C1-C3 alkylene chain which may be substituted with two C1-C2 alkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below:Type: GrantFiled: October 14, 2014Date of Patent: July 25, 2017Assignee: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Publication number: 20160264514Abstract: Provided is a pharmaceutical agent containing a compound represented by general formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof. A compound represented by general formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C1-C6 alkyl group; A represents a C1-C3 alkylene chain which may be substituted with two C1-C2 alkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below.Type: ApplicationFiled: October 14, 2014Publication date: September 15, 2016Applicant: TOA EIYO LTD.Inventors: Kazuhiro UEMOTO, Yoshimichi SATO, Naoki OKADA, Emiko IIMORI, Masayuki KAGEYAMA
-
Patent number: 9290440Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.Type: GrantFiled: April 15, 2013Date of Patent: March 22, 2016Assignee: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Publication number: 20150119418Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.Type: ApplicationFiled: April 15, 2013Publication date: April 30, 2015Applicant: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Patent number: 7875625Abstract: The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na+/H+ exchanger (NHE). There is provided a cyclohepta[b]pyridine-3-carbonylguanidine derivative represented by Formula (1): wherein R1 is a group selected from a sulfo group, a sulfoxy group, —OCONH—(CH2CH2O)n—SO3H and the following formulas: R2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; and n represents an integer from 1 to 10, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 16, 2006Date of Patent: January 25, 2011Assignee: Toa Eiyo Ltd.Inventors: Kazuhiro Uemoto, Koichi Takayanagi, Shin-ichi Kazayama
-
Publication number: 20090012114Abstract: The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na+/H+ exchanger (NHE). There is provided a cyclohepta[b]pyridine-3-carbonylguanidine derivative represented by Formula (1): wherein R1 is a group selected from a sulfo group, a sulfoxy group, —OCONH—(CH2CH2O)n—SO3H and the following formulas: R2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; and n represents an integer from 1 to 10, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 16, 2006Publication date: January 8, 2009Applicant: TOA Eiyo Ltd.Inventors: Kazuhiro Uemoto, Koichi Takayanagi, Shin-ichi Kazayama
-
Patent number: 7132409Abstract: 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5?-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.Type: GrantFiled: January 11, 2005Date of Patent: November 7, 2006Assignees: Toa Eiyo Ltd., Yamasa CorporationInventors: Takashi Konno, Kazuhiro Uemoto, Shinya Onuma, Yoshikazu Kato
-
Patent number: 6936596Abstract: 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5?-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.Type: GrantFiled: September 7, 2001Date of Patent: August 30, 2005Assignees: Toa Eiyo Ltd., Yamasa CorporationInventors: Takashi Konno, Kazuhiro Uemoto, Shinya Onuma, Yoshikazu Kato
-
Publication number: 20050130930Abstract: 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5?-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.Type: ApplicationFiled: January 11, 2005Publication date: June 16, 2005Applicants: TAO EIYO LTD., YAMASA CORPORATIONInventors: Takashi Konno, Kazuhiro Uemoto, Shinya Onuma, Yoshikazu Kato
-
Publication number: 20040053881Abstract: 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5′-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.Type: ApplicationFiled: September 5, 2003Publication date: March 18, 2004Inventors: Takashi Konno, Kazuhiro Uemoto, Shinya Onuma, Yoshikazu Kato